Physician profile
Malcolm B Oliver
NPI 1730278730
$1,651.70
in general payments reported to CMS, 2019-2025
24 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $47.98 · 2021: $70.10 · 2022: $129 · 2023: $312 · 2024: $356 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $215.94 | 2021-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $203.86 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $194.21 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $158.45 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $156.50 | 2024-2025 | Breztri, Airsupra |
| Abbott Laboratories | $101.01 | 2021-2024 | Freestyle Libre |
| Pfizer INC. | $75.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $62.86 | 2019 | |
| Exact Sciences Corporation | $62.23 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $49.63 | 2025 | Quviviq |
| Novartis Pharmaceuticals Corporation | $46.96 | 2020-2024 | |
| Vanda Pharmaceuticals INC. | $41.24 | 2023 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.95 | 2025 | Caplyta |
| Globus Medical, INC. | $33.57 | 2025 | Senza |
| Janssen Pharmaceuticals, INC | $27.78 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $23.81 | 2025 | Immunocap |
| Xeris Pharmaceuticals, INC. | $23.56 | 2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.35 | 2025 | Xifaxan |
| Astellas Pharma US INC | $22.87 | 2025 | Veozah |
| Axsome Therapeutics, INC. | $21.79 | 2023 | Auvelity |
| Collegium Pharmaceutical, INC. | $20.33 | 2020 | |
| Lundbeck LLC | $17.04 | 2025 | Rexulti |
| Smith+Nephew, INC. | $15.75 | 2022 | |
| Mylan Specialty L.P. | $14.06 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.